价格

AR-PROTAC

未知生产厂商

生成 AI 研报

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
- US 11098025 B2
  申请人: MONTELINO THERAPEUTICS INC优先权: 2019
  CN
  US
  3 件公开
- US 11547759 B2
  申请人: MONTELINO THERAPEUTICS INC优先权: 2020
  US
- US 2024376118 A1
  申请人: MONTELINO THERAPEUTICS INC优先权: 2022
  US
- US 11981672 B2
  申请人: MONTELINO THERAPEUTICS INC优先权: 2022
  US
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
CN 114163444 B申请人: 江苏恒瑞医药股份有限公司优先权: 2020
CN
Polypeptide of targeted androgen receptor, application of polypeptide and drug for preventing and treating prostatic cancer
CN 113912679 A申请人: FIRST AFFILIATED HOSPITAL MEDICAL COLLEGE XIAN JIAOTONG UNIV优先权: 2021
CN
DRUG FOR TREATING TRIPLE NEGATIVE BREAST CANCER
US 20250082764 A1申请人: HINOVA PHARMACEUTICALS INC优先权: 2022
US
PROTAC COMPOUNDS BINDING KEAP1 UBIQUITIN LIGASE FOR TARGETED PROTEIN DEGRADATION
WO 2025085815 A1申请人: SEED THERAPEUTICS US INC优先权: 2023
WO
Novel AR degradation agent as well as preparation method and application thereof
CN 120040529 A申请人: SHENZHEN LINGJI BIOLOGICAL TECH CO LTD优先权: 2023
CN
基于PROTAC策略的化合物及其制备方法、药物组合物和应用
CN 118164951 B申请人: 中国药科大学优先权: 2024
CN
COMBINATION OF KAT6 INHIBITOR AND AR PROTAC
WO 2026086887 A1申请人: JIANGSU HENGRUI PHARMACEUTICALS CO LTD优先权: 2024
WO
Multi-target difunctional chimera compound as well as preparation method and application thereof
CN 119504923 A申请人: THE FIRST AFFILIATED HOSPITAL OF ZHEJIANG UNIV COLLEGE OF MEDICINE THE FIRST HOSPITAL OF ZHEJIANG PR优先权: 2024
CN
PROTAC compound for targeted degradation of AR/AR-V7 as well as preparation method and application of PROTAC compound
CN 119798228 A申请人: UNIV CHANGZHOU优先权: 2025
CN

药物

AR-PROTAC

专利

Bi-functional compounds and methods for targeted ubiquitination of androgen receptor